tiprankstipranks
Promising Growth Potential for Day One Biopharmaceuticals Driven by Ojemda and FIREFLY-2 Trial
PremiumRatingsPromising Growth Potential for Day One Biopharmaceuticals Driven by Ojemda and FIREFLY-2 Trial
1M ago
Promising Growth and Strategic Advancements Drive Buy Rating for Day One Biopharmaceuticals
Premium
Ratings
Promising Growth and Strategic Advancements Drive Buy Rating for Day One Biopharmaceuticals
1M ago
Day One price target lowered to $36 from $40 at H.C. Wainwright
Premium
The Fly
Day One price target lowered to $36 from $40 at H.C. Wainwright
1M ago
Day One Biopharmaceuticals reports Q4 EPS ($1.02), consensus (35c)
PremiumThe FlyDay One Biopharmaceuticals reports Q4 EPS ($1.02), consensus (35c)
1M ago
DAWN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
DAWN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
Optimistic Buy Rating for Day One Biopharmaceuticals Driven by Strong Ojemda Performance and Promising Pipeline
Premium
Ratings
Optimistic Buy Rating for Day One Biopharmaceuticals Driven by Strong Ojemda Performance and Promising Pipeline
2M ago
Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but with Extreme Concentration Risk
PremiumMarket NewsDay One Biopharmaceuticals (DAWN) Posts Stellar Q3 but with Extreme Concentration Risk
4M ago
Day One price target lowered to $34 from $39 at JonesResearch
Premium
The Fly
Day One price target lowered to $34 from $39 at JonesResearch
4M ago
Day One Biopharmaceuticals Announces Leadership Transition
Premium
Company Announcements
Day One Biopharmaceuticals Announces Leadership Transition
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100